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Optimization of near-infrared fluorescent sentinel
lymph node mapping for vulvar cancer
Merlijn Hutteman, PhD; Joost R. van der Vorst, MD; Katja N. Gaarenstroom, MD, PhD; Alexander A. W. Peters, MD, PhD;
J. Sven D. Mieog, MD; Boudewijn E. Schaafsma, MD; Clemens W. G. M. Löwik, PhD; John V. Frangioni, MD, PhD;
Cornelis J. H. van de Velde, MD, PhD; Alexander L. Vahrmeijer, MD, PhDc
KOBJECTIVES: Near-infrared fluorescence imaging has the potential to
mprove sentinel lymph node mapping in vulvar cancer, which was as-
essed in the current study. Furthermore, dose optimization of indocya-
ine green adsorbed to human serum albumin was performed.
STUDY DESIGN: Nine vulvar cancer patients underwent the standard
sentinel lymph node procedure using 99mtechnetium-nancolloid and
atent blue. In addition, intraoperative imaging was performed after
eritumoral injection of 1.6 mL of 500, 750, or 1000 M of indocya-
nine green adsorbed to human serum albumin.
RESULTS: Near-infrared fluorescence sentinel lymph node mapping
was successful in all patients. A total of 14 sentinel lymph nodes (aver-
cancer. Am J Obstet Gynecol 2012;206:89.e1-5.age, 1.6; range, 1–4) were detected: 14 radioactive (100%), 11 blue
(79%), and 14 near-infrared fluorescent (100%).
CONCLUSION: This study demonstrates feasibility and accuracy of sen-
tinel lymph node mapping using indocyanine green adsorbed to human
serum albumin. Considering safety, cost, and pharmacy preferences,
an indocyanine green adsorbed to human serum albumin concentration
of 500 M appears optimal for sentinel lymph node mapping in vulvar
ancer.
ey words: image-guided surgery, indocyanine green, near-infrared
fluorescence imaging, sentinel lymph node mapping, vulvar cancer
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iVulvar cancer is a relatively rare dis-ease with an annual incidence of
approximately 4000 cases in the United
States, resulting in 900 deaths per year.1
Tumor size and invasion into adjacent
tissues are important factors for staging
vulvar cancers, but nodal status remains
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rticle title in the online Table of ContentsJANUARY 2012 Amerirate groin incisions.3 The lattermodification
as significantly decreased surgery-related
orbidity.3 However, 30% to 70% of
patients treated with full inguinofemoral
lymphadenectomy still suffer from lymp-
hedema.4-6 Only 27% of patients with clini-
cally stage I or II vulvar cancer have tumor
positive lymph nodes; therefore, approxi-
mately70%ofpatientsundergounnecessary
lymphadenectomy.6
The sentinel lymph node (SLN) biopsy,
as introduced in themanagement of cuta-
neous melanoma by Morton et al,7 was
rst described in vulvar cancer by Leven-
ack in 1994.8 The SLN procedure in vul-
ar cancer patients has been validated in
ulticenter trials and its introduction in
egular clinical practice has marked a sig-
ificant reduction in lymphedema,wound
nfection, andwounddehiscence.9, 10Cur-
rently, the procedure usually involves a
combination of a radioactive colloid and a
blue dye. However, the use of radiotracers
requires complex logistics including the
involvement of a nuclear medicine physi-
cian and the transport of radioactivity, and
is therefore not available in all clinics.
Moreover, blue dyes cannot be visualizedan
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Research Imaging www.AJOG.orgchannels are coveredby tissue, such as skin
or fat.
The use of invisible near-infrared (NIR)
light (700-900nm)has several characteris-
tics that can be advantageous in the SLN
procedure, which include relatively high
penetration into living tissue (millimeters
to centimeters), when comparedwith blue
dyes, and the lack of ionizing radiation.11
Indocyanine green (ICG) is one of only 2
clinically available NIR fluorescent agents
and is currently themost optimal agent for
SLN mapping.12 In several studies, intra-
perative imaging systems in combination
ith ICG have been used for the SLN pro-
edure for various typesof cancer.13-18The
lymphatic channels and SLNs in vulvar
cancer are often located in a relatively su-
perficial location in the groin when com-
pared with other tumors; therefore NIR
fluorescence imaging could be particularly
useful for this indication. Indeed, Crane et
al19 reported the successful use of ICG
lone at a concentration of 645 M, in
conjunction with an intraoperative imag-
ing systemfor theSLNprocedure invulvar
cancer. In that study involving 10 patients,
26 of 29 SLNs (90%)were detected in vivo
by NIR fluorescence. Furthermore, lym-
phatic channels could be visualized in 5 of
16 groins (31%) containing SLNs.
Preclinical evidence demonstrated that
premixing of ICG with human serum al-
bumin (HSA, complex is ICG:HSA) in-
creases the fluorescence intensity and hy-
drodynamic diameter of ICG, resulting in
TABLE 1
Patient and tumor characteristics
Patient Dose, M Age, y BMI
1 500 72 33
...................................................................................................................
2 500 30 22
...................................................................................................................
3 500 67 26
...................................................................................................................
4 750 37 29
...................................................................................................................
5 750 42 45
...................................................................................................................
6 750 37 23
...................................................................................................................
7 1000 72 27
...................................................................................................................
8 1000 50 26
...................................................................................................................
9 1000 74 32
...................................................................................................................
BMI, body mass index.
Hutteman. NIR fluorescent sentinel node mapping in vulvbetter retention in the SLN.20 The aims of m
89.e2 American Journal of Obstetrics& Gynecologhe current study were to assess the use of
IR fluorescence imaging using ICG:HSA
nd theMini-FLARE intraoperative imag-
ng systemfor theSLNprocedure invulvar
ancer and to optimize ICG:HSA dose.
MATERIALS AND METHODS
Preparation of ICG:HSA
ICG (25 mg vials) was purchased from
Pulsion Medical Systems (Munich, Ger-
many) and resuspended in 10mLof ster-
ile water for injection for the 500 M
roup, or in 5 mL of sterile water for in-
ection for the 750 M and 1000 M
groups, to yield stock solutions of 3.2
mM and 6.4 mM, respectively. Various
amounts of this stock solution were
transferred to a 50mL vial of Cealb (20%
HSA solution; Sanquin, Amsterdam,
The Netherlands) to yield ICG in HSA
(ICG:HSA) at a final concentration of
500 M, 750 M, or 1000 M.
Intraoperative NIR fluorescence
imaging
SLN mapping was performed using the
Mini-FLARE image-guided surgery sys-
tem as described in detail previously.14
Briefly, the system consists of 2 wave-
length separated light sources: a “white”
LED light source, generating 26,600 l
of 400 to 650 nm light to illuminate the
surgical field and an NIR LED light
source, generating 7.7 mW/cm2 of fluo-
escence excitation light.White light and
IR fluorescence images are acquired si-
Tumor localization Tumor size, mm
Right 22
..................................................................................................................
Right 10
..................................................................................................................
Left 10
..................................................................................................................
Midline 17
..................................................................................................................
Left 22
..................................................................................................................
Right 20
..................................................................................................................
Midline 6
..................................................................................................................
Midline 4
..................................................................................................................
Left 13
..................................................................................................................
ancer. Am J Obstet Gynecol 2012.ultaneously and displayed in real time, s
y JANUARY 2012sing custom designed optics and soft-
are. A pseudocolored (lime green) im-
ge of NIR fluorescence superimposed
ver the white light image is also dis-
layed, to provide the NIR fluorescence
ignal in proper anatomic context.
Clinical trial
The current dose escalation clinical trial
was approved by theMedical Ethics Com-
mittee of the Leiden University Medical
Center andwasperformed inconcordance
with the ethical standards of the Helsinki
Declaration of 1975. Nine consecutive pa-
tients that planned to undergo a SLN pro-
cedure forsquamouscell vulvarcarcinoma
were included in this study between June
2010 and January 2011. All patients had
clinically FIGO stage I vulvar cancerwith a
unifocal carcinoma measuring less than 4
cm in diameter, not encroaching the va-
gina, anus,orurethraandwithnegative in-
guinofemoral nodes as determined by pal-
pation and ultrasonography. Exclusion
criteria were pregnancy, lactation or an al-
lergy to iodine, shellfish, or indocyanine
green.
All patients gave informed consent
and were anonymized. Patients received
the standard-of-care SLN procedure.9
For our institution, this implies peritu-
moral injections of 60-100MBq 99mtech-
etium-nanocolloid on the afternoon of
he day before, or the morning before
urgery. Before the start of the operation,
mL total of patent blue V (Guerbet,
rance)was injected at 4 sites peritumor-
lly. Immediately after injection of pat-
nt blue, 1.6 mL total of ICG:HSA was
njected as 4 injections at the same loca-
ion as the patent blue injections. After
urgical scrub, theMini-FLARE imaging
eadwas positioned at approximately 30
m above the surgical field. The NIR flu-
rescence signal was measured percuta-
eously, before skin incision, and con-
inuously during the surgical procedure.
hroughout the procedure, the surgeon
as continuously provided with real-
ime NIR fluorescence image guidance.
hen the SLN could not be found easily
y NIR fluorescence, the handheld
amma probe could be used for the lo-
alization of SLNs. Relative brightness of
he SLNs was determined by measuring.........
.........
.........
.........
.........
.........
.........
.........
.........ignal-to-background ratios (SBRs), that
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www.AJOG.org Imaging Researchis the NIR fluorescence signal of the SLN
divided by a directly adjacent region. Ex-
cised SNLswere analyzed ex vivo forNIR
fluorescence and radioactivity and were
routinely analyzed by histopathologic
frozen section analysis. SLNs were fixed
in formalin and embedded in paraffin
for hematoxylin, eosin, and immunohis-
opathologic staining forAE1/AE3 atmul-
iple levels, with an interval of 250m, ac-
ording to the GROningen INternational
tudy on Sentinel nodes in Vulvar cancer
GROINSS-V) study protocol.9
Statistical analysis
For statistical analysis, SPSS statistical soft-
ware package (version 17.0; SPSS Inc, Chi-
cago, IL) was used. Graphswere generated
using GraphPad Prism Software (version
5.01;GraphPad,La Jolla,CA).Tocompare
the SBR between concentration groups, a
1-way analysis of variance (ANOVA) was
performedwith pairwise comparisonwith
least square difference (LSD) adjustment for
multiple comparisons. Assumption of ho-
mogeneity of variances was assessed using
Levene’s test. All statistical testswere 2-tailed
FIGURE 1
Sentinel lymph node mapping usin
Peritumoral injection of 1.6 mL of 500 M ICG:H
an be seen percutaneously (top row). Identific
uorescence imaging 17 minutes after injection
ars represent 1 cm.
HSA, human serum albumin; ICG, indocyanine green; NIR, near in
Hutteman. NIR fluorescent sentinel node mapping in vulvarandP .05was considered significant.RESULTS
Patient and tumor characteristics
Nine consecutive patients with vulvar
cancer undergoing SLN mapping were
included in this study. Patients and tu-
mor characteristics are described in Ta-
le 1. Median body mass index (BMI)
as 27 (range, 23–45), median age was
0 years (range, 30–72 years), and me-
ian tumor size was 13mm (range, 4–22
m). In 6 patients, the tumor was later-
lly located and in 3 patients the tumor
as located on, or near, the midline.
Intraoperative NIR fluorescence
imaging
Average time between ICG:HSA injec-
tion and skin incision was 19  4 min-
utes. In all patients (n 9), NIR fluores-
cence imaging using the Mini-FLARE
system enabled visualization of 1 or
more SLNs (Figure 1 and Supplementary
Video). Average time between skin inci-
sion and resection of the first SLN was
13 5 minutes. A total of 14 SLNs were
detected, all of which were radioactive
IR fluorescence imaging in vulvar ca
(injection site covered by hand) identifies lymph
n of the SLN (arrow) and 2 afferent lymphatic
G:HSA (bottom row). Camera exposure times we
d; SLN, sentinel lymph node.
er. Am J Obstet Gynecol 2012.and fluorescent (Table 2). Four SLNs
JANUARY 2012 Amerifrom 3 patients did not have blue stain-
ing from patent blue. After all NIR fluo-
rescent nodes were resected, the surgical
field was systematically inspected for re-
maining radioactivity or blue nodes. No
additional nodes were found that were
not detected by NIR fluorescence. No
adverse reactions associated with the use
of ICG:HSAor theMini-FLARE imaging
system were observed.
The effect of lymphatic tracer dose
on SLN brightness
The effect of injected lymphatic tracer
dose on fluorescence brightness was de-
termined by comparing SBRs between
concentration groups. Mean SBRs of
the SLNswere 12.3 2.9, 16.6 4.3, and
9.5 4.3 for the 500, 750, and 1000 M
concentration groups, respectively. A
1-wayANOVA showed no significant ef-
fect of concentration on SBR (P  .16),
and pairwise comparison with LSD
adjustment for multiple comparison
showed no difference between the indi-
vidual concentration and SBR, although
a trend was found for a decreased SBR of
er
channels, which converge in a SLN (arrow) that
nnels (arrowheads) is demonstrated using NIR
00 ms (top row) and 45 ms (bottom row). Scaleg N nc
SA atic
atio cha
of IC re 1
frare
cancthe 1000 M group when compared
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Research Imaging www.AJOG.orgwith the 750 M group (P .07). How-
ver, because of the small sample size, the
urrent pilot study may not have suffi-
ient power to detect significant differ-
nces in dose groups.
Percutaneous visualization
of lymphatic channels
The mean BMI of patients in which lym-
phatic channelswerevisualizedpercutane-
FIGURE 2
Optimization of ICG:HSA dose
Signal-to-background ratio (mean SD) of vul-
var SLNs (ordinate) is plotted as a function of
injected dose of ICG:HSA (abscissa). The SBRs of
the 500, 750, and 100 M concentration
roups were not significantly different, although
trend was found favoring 750 M over 1000
M (P .07).
HSA, human serum albumin; ICG, indocyanine green; SBR, signal-
to-background ratio; SLN, sentinel lymph node.
Hutteman. NIR fluorescent sentinel node mapping in vulvar
cancer. Am J Obstet Gynecol 2012.
TABLE 2
SLN identification results
Patient
Number of SLN
detected Radiocolloid B
1 2 (1 left, 1 right) 2
...................................................................................................................
2 1 (right) 1
...................................................................................................................
3 1 (left) 1
...................................................................................................................
4 2 (1 right, 1 left) 2
...................................................................................................................
5 1 (left) 1
...................................................................................................................
6 1 (right) 1
...................................................................................................................
7 1 (left) 1
...................................................................................................................
8 4 (2 left, 2 right) 4
...................................................................................................................
9 1 (left) 1
...................................................................................................................
Total 14 14 (100%) 1
...................................................................................................................
NIR, near infrared; SLN, sentinel lymph node; SLN, number
Hutteman. NIR fluorescent sentinel node mapping in vulv89.e4 American Journal of Obstetrics& Gynecologously to all SLN containing groins (n 5
patients) was 24.8 2.2. In patients with
bilateral SLNs inwhichpercutaneousvisu-
alization was possible for the groin (n 2
atients), the mean BMI was 31.0  2.8,
nd inpatientswherepercutaneousvisual-
zationof lymphatic channelswas not pos-
ible (n 2 patients), the mean BMI was
8.59.2.A1-wayANOVAshoweda sig-
ificant difference in the BMIs between
hese 3 groups (P .024).Apairwise com-
arison with LSD adjustment for multiple
omparison showed a significantly higher
MI for the group in which percutaneous
isualization of lymphatic channels was
ot possible, when compared with the
roup inwhichpercutaneousvisualization
f lymphatic channels was possible (P 
009).
COMMENT
The current study showed feasibility and
accuracy of SLNmapping in vulvar cancer
using ICG:HSA and the Mini-FLARE im-
aging system. In all 9 cases, the Mini-
FLARE permitted the gynecologist to
perform SLN mapping under direct im-
age-guidance after skin incision. The flex-
ible gooseneck of the Mini-FLARE could
be used to position the system at any re-
quired location over the surgical field,
which ensured no interference with the
procedure. Indeed, no additional timewas
NIR
fluorescence SLN
Percutaneous
visualization
2 0 Unilateral
..................................................................................................................
1 0 Yes
..................................................................................................................
1 1 Yes
..................................................................................................................
2 0 Unilateral
..................................................................................................................
1 0 No
..................................................................................................................
1 0 Yes
..................................................................................................................
1 0 Yes
..................................................................................................................
4 0 Yes
..................................................................................................................
1 1 No
..................................................................................................................
9%) 14 (100%) 2 8 of 12 groins
..................................................................................................................
LNs containing tumor cells.
ancer. Am J Obstet Gynecol 2012.needed to complete theprocedure,with an
y JANUARY 2012average time between skin incision and re-
section of the first SLN of 13 5minutes.
All radioactive SLNs could also be de-
ected by NIR fluorescence. This higher
etectability compared with the study by
rane et al19 that used ICG alonemay be
ue to improved brightness of ICG:HSA
ver ICG, better retention in the SLN,
etter imaging system performance, an
ptimized tradeoff between injection
oncentration and tracer dilution within
ymphatic channels, or a combination
hereof.14 In contrast, 4 of 14 SLNs could
not be detected by patent blue, which is
comparable to previous findings.10,19,21
Lymphatic channels could be visualized
in themajority of patients before skin in-
cision. This aided the gynecologist in de-
termining the location of the incision
and facilitated a more efficient identifi-
cation of SLNs. In the patients in whom
percutaneous visualization of lymphatic
channels was not possible, a higher BMI
was observed when compared with pa-
tients in whom the lymphatic channels
could be visualized percutaneously.
Crane et al19 observed similar findings.
uture studies will have to determine
hether NIR fluorescence imaging can
eplace radiocolloids in the SLN proce-
ure in vulvar cancer, which could po-
entially be feasible only in nonobese
atients. This could be particularly ben-
ficial in clinics where radiotracers are
ot available. Furthermore, as the pa-
ient population in Western societies
ends to have increasingly higher BMIs,
he penetration depth has to be increased
or NIR fluorescence imaging to be a
enerally usable imaging modality. To
ccomplish this, current research is fo-
using on improved fluorophores (some
f which are currently in the process of
linical approval22) and improved cam-
ra systems using optimized detection
echniques to maximize the depth at
hich afluorophore canbe detected.23,24
In the current study, no significant dif-
ferences in NIR fluorescence signal were
observed between the different concen-
trations that were administered. How-
ever, a trend was observed showing a de-
cline of signal in the 1000 M group
(Figure 2), which is in line with previ-
ously reported results in breast cancer.14lue
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www.AJOG.org Imaging Researchincrease in concentration can be ex-
plained by an effect in fluorescence
quenching.12 Fluorescence quenching
ccurs when the concentration of a fluo-
ophore is too high, causingmolecules to
bsorb the emitted light of other nearby
olecules, thereby effectively attenuat-
ng the fluorescence signal. In the cur-
ent study, ICGwas adsorbed toHSAbe-
ore injection. Preclinical work has
hownpremixing to increase the fluores-
ence brightness of ICG and improve re-
ention in the SLN.20 Flow to higher tier
odes seemed to have been avoided, as
o additional NIR fluorescent nodes
ere identified thatwere not radioactive.
n ongoing study is investigating
hether the albumin is actually needed
or optimal SLNmapping in vulvar can-
er. When the optimal imaging parame-
ers have been determined, larger trials
an be performed to assess patient
enefit.
In conclusion, the current study dem-
nstrates the feasibility of SLN mapping
n vulvar cancer patients using ICG:HSA
nd the Mini-FLARE image-guided sur-
ery system. The preferred dose can be
etermined by local preparation prefer-
nces because no differences between
ested doses were observed. In general, a
ose of 500Mseemed to be optimal, as
t requiresminimalmanipulation of ICG
nd albumin volumes. f
ACKNOWLEDGMENTS
We thank Dorien M.A. Berends-van der Meer
andMargriet J.G. Löwik for their assistancewith
inclusion of patients, and Lindsey Gendall for
editing.
REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer sta-
tistics, 2010. CA Cancer J Clin 2010;60:
277-300.2. Hacker NF. Revised FIGO staging for carci-
noma of the vulva. Int J Gynaecol Obstet
2009;105:105-6.
3. Ansink A, Van Der Velden J. Surgical inter-
ventions for early squamous cell carcinoma of
the vulva. Cochrane Database SystemRev (On-
line) 2000:CD002036.
4. Gaarenstroom KN, Kenter GG, Trimbos JB,
et al. Postoperative complications after vulvec-
tomy and inguinofemoral lymphadenectomy
using separate groin incisions. Int J Gynecol
Cancer 2003;13:522-7.
5. Rouzier R, Haddad B, Dubernard G, Dubois
P, Paniel BJ. Inguinofemoral dissection for car-
cinoma of the vulva: effect of modifications of
extent and technique on morbidity and survival.
J Am Coll Surg 2003;196:442-50.
6. De Hullu JA, Van Der Zee AG. Surgery and
radiotherapy in vulvar cancer. Crit Rev Oncol
Hematol 2006;60:38-58.
7. Morton DL, Wen DR, Wong JH, et al. Tech-
nical details of intraoperative lymphatic map-
ping for early stage melanoma. Arch Surg
1992;127:392-9.
8. Levenback C, Burke TW, Gershenson DM,
Morris M, Malpica A, Ross MI. Intraoperative
lymphatic mapping for vulvar cancer. Obstet
Gynecol 1994;84:163-7.
9. VanDer Zee AG,OonkMH,DeHullu JA, et al.
Sentinel node dissection is safe in the treatment
of early-stage vulvar cancer. J Clin Oncol
2008;26:884-9.
10. Hampl M, Hantschmann P, Michels W, Hil-
lemanns P, German Multicenter Study Group.
Validation of the accuracy of the sentinel lymph
node procedure in patients with vulvar cancer:
results of a multicenter study in Germany. Gy-
necol Oncol 2008;111:282-8.
11. Frangioni JV. In vivo near-infrared fluores-
cence imaging. Curr Opin Chem Biol 2003;
7:626-34.
12. Gioux S, Choi HS, Frangioni JV. Image-
guided surgery using invisible near-infrared
light: fundamentals of clinical translation. Mol
Imaging 2010;9:237-55.
13. Hojo T, Nagao T, Kikuyama M, Akashi S,
Kinoshita T. Evaluation of sentinel node biopsy
by combined fluorescent and dye method and
lymph flow for breast cancer. Breast 2010;
19:210-3.
14. Mieog JS, Troyan SL, Hutteman M, et al.
Towards optimization of imaging system and
lymphatic tracer for near-infrared fluorescent
JANUARY 2012 Amerisentinel lymph node mapping in breast cancer.
Ann Surg Oncol 2011;18:2483-91.
15. Troyan SL, Kianzad V, Gibbs-Strauss SL, et
al. The FLARE intraoperative near-infrared fluo-
rescence imaging system: a first-in-human clin-
ical trial in breast cancer sentinel lymph node
mapping. Ann Surg Oncol 2009;16:2943-52.
16. Murawa D, Hirche C, Dresel S, Hunerbein
M. Sentinel lymph node biopsy in breast cancer
guided by indocyanine green fluorescence. Br J
Surg 2009;96:1289-94.
17. Crane LM, Themelis G, Pleijhuis RG, et al.
Intraoperative multispectral fluorescence imag-
ing for the detection of the sentinel lymph node
in cervical cancer: a novel concept. Mol Imaging
Biol 2010 Sep 11 [Epub ahead of print].
18. Fujiwara M, Mizukami T, Suzuki A, Fuka-
mizu H. Sentinel lymph node detection in skin
cancer patients using real-time fluorescence
navigation with indocyanine green: preliminary
experience. J Plast Reconstr Aesthet Surg
2009;62:e373-8.
19. Crane LM, Themelis G, Arts HJ, et al. Intra-
operative near-infrared fluorescence imaging
for sentinel lymph node detection in vulvar can-
cer: first clinical results. Gynecol Oncol 2011;
120:291-5.
20. Ohnishi S, Lomnes SJ, Laurence RG, Gog-
bashian A, Mariani G, Frangioni JV. Organic al-
ternatives to quantum dots for intraoperative
near-infrared fluorescent sentinel lymph node
mapping. Mol Imaging 2005;4:172-81.
21. Rob L, Robova H, Pluta M, et al. Further
data on sentinel lymph node mapping in vulvar
cancer by blue dye and radiocolloid Tc99. Int J
Gynecol Cancer 2007;17:147-53.
22. Marshall MV, Draney D, Sevick-Muraca EM,
Olive DM. Single-dose intravenous toxicity
study of IRDye 800CW in Sprague-Dawley rats.
Mol Imaging Biol 2010;12:583-94.
23. Gioux S, Mazhar A, Cuccia DJ, Durkin AJ,
Tromberg BJ, Frangioni JV. Three-dimensional
surface profile intensity correction for spatially
modulated imaging. J Biomed Opt 2009;14:
034045.
24. Kumar AT, Raymond SB, Bacskai BJ, Boas
DA. Comparison of frequency-domain and
time-domain fluorescence lifetime tomography.
Opt Lett 2008;33:470-2.can Journal of Obstetrics& Gynecology 89.e5
